UBS AM
PRVB

UBS AM’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

UBS AM’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-116,324
Closed -$2.8M – 2757
2023
Q2 		$2.8M Hold
116,324
– – ﹤0.01% 1493
2023
Q1 		$2.8M Buy
116,324
+48,279
+71% +$606K ﹤0.01% 1493
2022
Q4 		$719K Buy
68,045
+38,329
+129% +$309K ﹤0.01% 2017
2022
Q3 		$134K Sell
29,716
-22,135
-43% -$101K ﹤0.01% 2658
2022
Q2 		$207K Buy
51,851
+181
+0.4% +$858 ﹤0.01% 2574
2022
Q1 		$378K Buy
51,670
+1,048
+2% +$6.27K ﹤0.01% 2541
2021
Q4 		$284K Buy
50,622
+10,411
+26% +$66.1K ﹤0.01% 2690
2021
Q3 		$257K Buy
40,211
+511
+1% +$3.28K ﹤0.01% 2649
2021
Q2 		$335K Buy
39,700
+12,400
+45% +$100K ﹤0.01% 2629
2021
Q1 		$287K Hold
27,300
– – ﹤0.01% 2494
2020
Q4 		$462K Hold
27,300
– – ﹤0.01% 2322
2020
Q3 		$350K Hold
27,300
– – ﹤0.01% 2270
2020
Q2 		$385K Buy
+27,300
New +$345K ﹤0.01% 2214

UBS AM's PRVB Position: Q3 2023 in Review

UBS AM sold out of Provention Bio, Inc. Common Stock (PRVB) in Q3 2023, closing a stake of 116,324 shares — an estimated $2.8M sold.

UBS AM first reported a position in PRVB in Q2 2020 and held it in 13 quarters. The position peaked at $2.8M in Q2 2023. 0 funds tracked by Wall St. Rank hold PRVB as of Q3 2023.

  • UBS AM reported no remaining Provention Bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • UBS AM sold 116,324 Provention Bio, Inc. Common Stock shares in Q3 2023, an estimated $2.8M.
  • UBS AM first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 13 quarters.
  • UBS AM's Provention Bio, Inc. Common Stock position peaked at $2.8M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2023.

Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.